Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-12-27
2010-06-08
Harris, Alana M (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000, C435S007100, C435S007400, C436S063000, C436S064000, C436S086000, C436S174000, C514S001000, C514S002600, C514S004300, C424S001110, C424S009100, C424S009200
Reexamination Certificate
active
07732159
ABSTRACT:
The present invention describes clinically and medically important methods of examining, screening over time, and monitoring the outcome of a cancer patient who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease, or the effectiveness of cancer treatment, in a cancer patient by measuring the levels of one or more analytes of the plasminogen activator (uPA) system, namely, uPA, PAI-1 and the complex of uPA:PAI-1, in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment. As a result of performing the method, an increase or elevation in the levels of one or more of the PA system analytes in the cancer patient compared with the levels one or more of the respective PA system analytes in normal control individuals serves as an indicator of cancer advancement or progression and/or a lack of treatment effectiveness for the patient.
REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5122464 (1992-06-01), Wilson et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5422245 (1995-06-01), Nielsen et al.
patent: 5427908 (1995-06-01), Dower et al.
patent: 5516637 (1996-05-01), Huang et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5580717 (1996-12-01), Dower et al.
patent: 5658727 (1997-08-01), Barbas et al.
patent: 5698426 (1997-12-01), Huse
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5750753 (1998-05-01), Kimae et al.
patent: 5780225 (1998-07-01), Wigler et al.
patent: 5821047 (1998-10-01), Garrard et al.
patent: 5969108 (1999-10-01), McCafferty et al.
patent: 2002/0012950 (2002-01-01), Nielsen et al.
patent: WO 86/05807 (1986-10-01), None
patent: WO 89/01036 (1989-02-01), None
patent: WO 02/099114 (2002-12-01), None
Perkins and Schisterman, “The inconsistency of ‘optimal’ cutpoints obtained using two criteria based on the receiver operating characteristic curve,”Am J Epidemiol., 163(7): 670-675 (Apr. 1, 2006; epub Jan. 12, 2006) Abstract.
Tockman et al., “Considerations in Bringing a Cancer Biomarker to Clinical Application,”Cancer Research(Suppl.). 52: 2711s-2718s (May 1, 1992).
Konecny et al., “Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer,”Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, Jun. 2001, 7(6), pp. 1743-1749.
Miyake et al., “Elevation of urokinase-type plasminogen activator its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer,”International Journal of Oncology, Mar. 1999, 14(3), pp. 535-541.
Yang et al., “Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets,”International Journal of Cancer, Sep. 20, 2000, 89(5), pp. 431-439; Abstract.
Foekens et al., “The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients,”Cancer Research, Feb. 1, 2000, 60(3), pp. 636-643; Abstract.
Look et al., “Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients,”Journal of the National Cancer Institute, Jan. 16, 2002, 94(2), pp. 116-128; Abstract.
Broet et al., “Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study,”British Journal of Cancer, May 1999, 80(3-4), pp. 536-545; Abstract.
Lox et al., “Tamoxifen-induced changes in the plasma fibrinolytic factors in menopausal women with breast cancer,”Clinical and Applied Thrombosis/Hemostasis, 1997, 3(4), pp. 234-238; Abstract.
Morii et al., “Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma,”Anticancer Research, Sep. 2000, 20(5A), pp. 3031-3036; Abstract.
Pedersen et al., “Determination of the complex between urokinase and its type-1 inhibitor in plasma from healthy donors and breast cancer patients,”Clinical Chemistry, Aug. 1999, 45(8), pp. 1206-1213; Abstract.
Nielsen et al., “Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer,”Annals of Surgical Oncology, Sep. 2000, 7(8),Lippincott Williams & Wilkins, pp. 617-623; Abstract.
Supplemental European Search Report Dated Jul. 4, 2006 Corresponding to European Patent Application No. 03 71 1275.
Köhler et al., “Continuous cultures of fused cells secreting antibody of predefined specificity.”Nature, Aug. 7, 1975, 256(5517), pp. 495-497.
Kozbor et al., “The production of monoclonal antibodies from human lymphocytes,”Immunology Today, 1983, 4(3), pp. 72-79.
Cole et al., “The EBV-Gybridoma technique and its application to human lung cancer,”Monoclonal Antibodies and Cancer Therapy, 1985, Alan R. Liss, Inc., New York, pp. 77-96.
Andreasen et al., “The Urokinase-type plasminogen activator system in cancer metastasis: a review,”International Journal of Cancer, Jul. 3, 1997, 72(1), pp. 1-22.
Dewitte et al., “Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients,”British Journal of Cancer, Mar. 1999, 79(7/8), pp. 1190-1198.
Liotta et al., “Role of collagenases in tumor cell invasión,”Cancer Metastasis Review, 1982, 1(1), Martinus Nijhoff Publishers, the Hague, the Netherlands, pp. 277-288.
Danø et al., “Plasminogen activators, tissue degradation, and cancer,”Advances in Cancer Research, Klein et al. (eds.), 1985, 44, Academic Press, Inc., pp. 139-266.
Mignatti et al., “Biology and biochemistry of proteinases in tumor invasion,”Physiological Reviews., Jan. 1993, 73(1), The American Physiological Society, pp. 161-195.
Grondahl-Hansen et al., “Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans,”American Journal of Pathology, Jan. 1991, 138(1), pp. 111-117.
Pyke et al., “The plasminogen activation system in human colon cancer: Messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma,”Cancer Research, Aug. 1, 1991, 51(15), pp. 4067-4071.
Bacharach et al., “In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis,”Proceedings of the National Academy of Sciences of the USA, Nov. 5, 1992, 89(22), pp. 10686-10690.
Duffy, “The role of proteolytic enzymes in cancer invasion and metastasis,”Clinical Experimental Metastasis, May 1992, 10(3), Rapid Communications of Oxford, pp. 145-155.
Pöllänen et al., “Directed plasminogen activation at the surface of normal and malignant cells,”Advances in Cancer Research, 1991, 57, Academic Press, Inc., pp. 273-328.
Ossowski, “Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase,”Cancer Research, Dec. 15, 1992, 52(24), pp. 6754-6760.
Blasi et al., “Urokinase-dependent cell surface proteolysis and cancer,”Seminars in Cancer Biology: The Role of Proteases in Cancer, Apr. 1990, 1 (2), pp. 117-126.
Chapman et al., “Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration,”Current Opinion in Cell Biology, Oct. 1997, 9(5), Current Biology, Ltd., pp. 714-724.
Deng et al., “The PAI-1/vitronectin interaction: two cats in a bag?”Thrombosis and Haemostasis, Jul
Carney Walter P.
Hamer Peter J.
Harris Alana M
Siemens Healthcare Diagnostics Inc.
Stein Kevin
LandOfFree
Assays for cancer patient monitoring based on levels of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Assays for cancer patient monitoring based on levels of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assays for cancer patient monitoring based on levels of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4244732